Early identification initiative for neurocognitive disorders
Innovation
On going
Context
Alzheimer’s disease and neurocognitive disorders are now a major public health issue and represent an immense burden for patients, caregivers, healthcare professionals, and the healthcare system as a whole.
The latest advances in diagnosis and therapeutic innovations that can impact the development of the disease have the potential to profoundly change our approach to the disease.
Project description
The therapies currently in development particularly target patients in the early stages of neurocognitive disorders. Moreover, mild neurocognitive disorders are not always detected because the symptoms do not manifest themselves in an obvious way for the patient and their surroundings. Finally, non-pharmaceutical approaches (healthy lifestyle habits, comorbidity treatments, etc.) could delay the progression of the disease towards symptomatic phases.
The initiative proposed by Montréal InVivo aims to develop the healthcare system’s ability to detect and diagnose neurocognitive disorders at the appropriate time.